Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Therapeutic Drug Monitoring of Lopinavir in HIV-Infected Children on Second-Line Antiretroviral Therapy in Asia.

Aurpibul L, Teerananchai S, Prasitsuebsai W, Sudjaritruk T, Kosalaraksa P, Kurniati N, Truong KH, Do VC, Nguyen LV, Chokephaibulkit K, Singtoroj T, Kerr SJ.

Ther Drug Monit. 2016 Dec;38(6):791-795.

PMID:
27749514
2.

Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.

Prasitsuebsai W, Teeraananchai S, Singtoroj T, Truong KH, Ananworanich J, Do VC, Nguyen LV, Kosalaraksa P, Kurniati N, Sudjaritruk T, Chokephaibulkit K, Kerr SJ, Sohn AH.

J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):380-6. doi: 10.1097/QAI.0000000000000971.

PMID:
27355415
3.

Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children.

Prasitsuebsai W, Kerr SJ, Truong KH, Ananworanich J, Do VC, Nguyen LV, Kurniati N, Kosalaraksa P, Sudjaritruk T, Chokephaibulkit K, Thammajaruk N, Singtoroj T, Teeraananchai S, Horng H, Bacchetti P, Gandhi M, Sohn AH.

AIDS Res Hum Retroviruses. 2015 Oct;31(10):1009-14. doi: 10.1089/AID.2015.0111.

4.

Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals.

Jiamsakul A, Chaiwarith R, Durier N, Sirivichayakul S, Kiertiburanakul S, Van Den Eede P, Ditangco R, Kamarulzaman A, Li PC, Ratanasuwan W, Sirisanthana T; TREAT Asia Studies to Evaluate Resistance--Monitoring Study TASER-M..

J Med Virol. 2016 Feb;88(2):234-43. doi: 10.1002/jmv.24320.

PMID:
26147742
5.

Implementation and Operational Research: Effects of CD4 Monitoring Frequency on Clinical End Points in Clinically Stable HIV-Infected Patients With Viral Suppression.

Ahn JY, Boettiger D, Law M, Kumarasamy N, Yunihastuti E, Chaiwarith R, Lee MP, Sim BL, Oka S, Wong W, Kamarulzaman A, Kantipong P, Phanuphak P, Ng OT, Kiertiburanakul S, Zhang F, Pujari S, Ditangco R, Ratanasuwan W, Merati TP, Saphonn V, Sohn AH, Choi JY; TREAT Asia HIV Observational Databases (TAHOD)..

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):e85-92. doi: 10.1097/QAI.0000000000000634.

6.

Transmission Networks of HIV-1 Among Men Who Have Sex With Men in East and Southeast Asia.

Tee KK, Kantor R, Sungkanuparph S, Takebe Y, Li P, Ditangco R, Phanuphak P, Sirisanthana T, Sim B, Ratanasuwan W, Kantipong P, Kamarulzaman A; TREAT Asia Studies to Evaluate Resistance-Monitoring (TASER-M) Database..

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):e28-30. doi: 10.1097/QAI.0000000000000614. No abstract available.

7.

Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007-2010) - TASER-S.

Jiamsakul A, Sirivichayakul S, Ditangco R, Wong KH, Li PC, Praparattanapan J, Phanuphak P, Segubre-Mercado E, Yam WC, Sirisanthana T, Singtoroj T, Law M; TREAT Asia Studies to Evaluate Resistance – Surveillance Study (TASER-S)..

AIDS Res Ther. 2015 Feb 13;12:3. doi: 10.1186/s12981-015-0043-1.

8.

HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.

Jiamsakul A, Sungkanuparph S, Law M, Kantor R, Praparattanapan J, Li PC, Phanuphak P, Merati T, Ratanasuwan W, Lee CK, Ditangco R, Mustafa M, Singtoroj T, Kiertiburanakul S; TREAT Asia Studies to Evaluate Resistance – Monitoring Study (TASER-M)..

J Int AIDS Soc. 2014 Aug 19;17:19053. doi: 10.7448/IAS.17.1.19053.

9.

Relationship between hyperglycemia and the risk of tuberculosis in Asian HIV-positive individuals in the antiretroviral therapy era: cohort study.

Achhra AC, Pujari S, Choi JY, Khusuwan S, Kinh NV, Phanuphak P, Chaiwarith R, Lee MP, Saphonn V, Kiertiburanakul S, Thuy PT, Law MG; TREAT Asia HIV Observational Database (TAHOD) Cohort..

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):e108-11. doi: 10.1097/QAI.0000000000000217. No abstract available.

10.

Factors associated with suboptimal adherence to antiretroviral therapy in Asia.

Jiamsakul A, Kumarasamy N, Ditangco R, Li PC, Phanuphak P, Sirisanthana T, Sungkanuparph S, Kantipong P, K C Lee C, Mustafa M, Merati T, Kamarulzaman A, Singtoroj T, Law M; TREAT Asia Studies to Evaluate Resistance Monitoring Study (TASER-M)..

J Int AIDS Soc. 2014 May 16;17:18911. doi: 10.7448/IAS.17.1.18911.

11.

Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients.

Kiertiburanakul S, Boettiger D, Lee MP, Omar SF, Tanuma J, Ng OT, Durier N, Phanuphak P, Ditangco R, Chaiwarith R, Kantipong P, Lee CK, Mustafa M, Saphonn V, Ratanasuwan W, Merati TP, Kumarasamy N, Wong WW, Zhang F, Pham TT, Pujari S, Choi JY, Yunihastuti E, Sungkanuparph S; TREAT Asia HIV Observational Databases (TAHOD).; TREAT Asia Studies to Evaluate Resistance (TASER)..

J Int AIDS Soc. 2014 Mar 14;17:18804. doi: 10.7448/IAS.17.1.18804.

12.

Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.

Phanuphak P, Sirivichayakul S, Jiamsakul A, Sungkanuparph S, Kumarasamy N, Lee MP, Sirisanthana T, Kantipong P, Lee C, Kamarulzaman A, Mustafa M, Ditangco R, Merati T, Ratanasuwan W, Singtoroj T, Kantor R.

J Acquir Immune Defic Syndr. 2014 May 1;66(1):74-9. doi: 10.1097/QAI.0000000000000108.

13.

Rilpivirine resistance-associated mutations among antiretroviral-naive patients infected with HIV-1 in Asia.

Sungkanuparph S, Jiamsakul A, Kiertiburanakul S, Sirivichayakul S, Praparattanapan J, Kantor R; TREAT Asia Studies to Evaluate Resistance..

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):e98-100. doi: 10.1097/QAI.0b013e31827a34b2. No abstract available.

14.

Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa.

Land S, Zhou J, Cunningham P, Sohn AH, Singtoroj T, Katzenstein D, Mann M, Sayer D, Kantor R.

J Int AIDS Soc. 2013 Jul 10;16:18580. doi: 10.7448/IAS.16.1.18580.

15.

Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B.

Oyomopito RA, Li PC, Sungkanuparph S, Phanuphak P, Tee KK, Sirisanthana T, Kantipong P, Oka S, Lee CK, Kamarulzaman A, Choi JY, Sohn AH, Law M, Chen YM; TREAT Asia Studies to Evaluate Resistance (TASER) and The TREAT Asia HIV Observational Database..

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):293-300. doi: 10.1097/QAI.0b013e31827a2e8f.

16.

Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis.

Jiamsakul A, Kantor R, Li PC, Sirivichayakul S, Sirisanthana T, Kantipong P, Lee CK, Kamarulzaman A, Ratanasuwan W, Ditangco R, Singtoroj T, Sungkanuparph S; TREAT Asia Studies to Evaluate Resistance – Monitoring Study (TASER-M)..

BMC Res Notes. 2012 Oct 24;5:582. doi: 10.1186/1756-0500-5-582.

17.

HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study.

Sungkanuparph S, Oyomopito R, Sirivichayakul S, Sirisanthana T, Li PC, Kantipong P, Lee CK, Kamarulzaman A, Messerschmidt L, Law MG, Phanuphak P; TREAT Asia Studies to Evaluate Resistance-Monitoring Study (TASER-M)..

Clin Infect Dis. 2011 Apr 15;52(8):1053-7. doi: 10.1093/cid/cir107.

18.

Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

Hamers RL, Oyomopito R, Kityo C, Phanuphak P, Siwale M, Sungkanuparph S, Conradie F, Kumarasamy N, Botes ME, Sirisanthana T, Abdallah S, Li PC, Ngorima N, Kantipong P, Osibogun A, Lee CK, Stevens WS, Kamarulzaman A, Derdelinckx I, Chen YM, Schuurman R, van Vugt M, Rinke de Wit TF; PharmAccess African PASER and TREAT Asia Studies to Evaluate Resistance..

Int J Epidemiol. 2012 Feb;41(1):43-54. doi: 10.1093/ije/dyq192. No abstract available.

19.

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

Wattanagoon Y, Stepniewska K, Lindegårdh N, Pukrittayakamee S, Silachamroon U, Piyaphanee W, Singtoroj T, Hanpithakpong W, Davies G, Tarning J, Pongtavornpinyo W, Fukuda C, Singhasivanon P, Day NP, White NJ.

Antimicrob Agents Chemother. 2009 Mar;53(3):945-52. doi: 10.1128/AAC.00588-08.

20.

Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria.

Ashley EA, Stepniewska K, Lindegårdh N, McGready R, Annerberg A, Hutagalung R, Singtoroj T, Hla G, Brockman A, Proux S, Wilahphaingern J, Singhasivanon P, White NJ, Nosten F.

Trop Med Int Health. 2007 Feb;12(2):201-8.

Items per page

Supplemental Content

Loading ...
Support Center